2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen

NCT00191971 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Urologic Neoplasms
Carcinoma, Transitional Cell

Interventions

DRUG: Gemcitabine

Sponsor

Eli Lilly and Company